Figure 4 from A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results

Le résumé fourni par la source

Effect of HCQ + SI treatment on the plasma lipidome. A, Average fold change (posttreatment/baseline) of individual lipid species. B, Scatter plots showing a significant positive correlation between the fold change of key treatment-altered lipid species and PSA-PFS time. C, Heatmap of the fold change (posttreatment/baseline) for lipids that are significantly different between patients with longer (>5 months) vs. shorter (≤5 months) PSA-PFS time. AC, acylcarnitines; AC-OH, hydroxylated acylcarnitines; BA, bile acids; CE, cholesteryl esters; Cer, ceramides; CIP, ceramide phosphates; CoQ10, coenzyme Q10; DE, dehydrocholesteryl esters; deDE, dehydrodesmosteryl esters; DG, diacylglycerols; FFA, free fatty acids; HexCer, hexosylceramides; LPC(O), lysophosphatidylcholines with an O-alkyl chain; LPC, lysophosphatidylcholines; LPE, lysophosphatidylethanolamines; LPI, lysophosphatidylinositols; OxSpecies, oxidized lipid species; PA, phosphatidic acids; PC, phosphatidylcholines; PE, phosphatidylethanolamines; PG, phosphatidylglycerols; PI, phosphatidylinositols; PS, phosphatidylserines; SHexCer, sulfatides (sulfated hexosylceramides); SM/Sph, sphingomyelins; TG(O), ether-linked triacylglycerols; TG, triacylglycerols.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.